UNICYSTIC Ameloblastoma of the Mandible About a Case and Review of the Literature
Hafida Mahchouche1, Fadila Saoudi2, Fatma Alloun3 and Rachid
1Department of Pathology and Oral Surgery, University Hospital of Beni-Messous, Algeria
2Professor, Department of Periodontology, CHU of Béni-Messous, Algeria
3Professor, Department of Epidemiology, CHU of Béni-Messous, Algeria
4Professor, Head of Department of Pathology and Oral Surgery, University Hospital of Beni-Messous, Algeria
*Corresponding Author: Hafida Mahchouche, Department of Pathology and Oral Surgery, University Hospital of Beni-Messous, Algeria.
Received: March 27, 2023; Published: April 25, 2023
Unicystic ameloblastoma is a rare benign entity which represents 5-15% of all intraosseous ameloblastomas, less aggressive and less invasive, which is observed mainly in younger patients. We report a case of unicystic ameloblastoma in a 25-year-old woman with a rapid evolution in a few months in the symphyseal and parasymphyseal region and illustrate the complexity of the differential diagnosis and the means of management with a brief review of recent literature.
Keywords:Ameloblastoma; Unicystic Ameloblastoma; Genetic Mutation
- Robinson L and Martinez MG. “Unicystic ameloblastoma. A prognostically distinct entity”. Cancer5 (1977): 2278-2285.
- Gardner DG and Corio RL “Plexiform unicysticameloblastoma: A variant of ameloblastoma with a low-recurrence rate after enucleation”. Cancer 53 (1984): 1730-1735.
- Kim SW., et al. “Conservative surgical treatment for ameloblastoma: a report of three cases”. Journal of the Korean Association of Oral and Maxillofacial Surgeons5 (2018): 242-247.
- Haq J., et al . “Argument for the conservative management of mandibular ameloblastomas”. British Journal of Oral and Maxillofacial Surgery9 (2016): 1001-1005.
- Hollows P., et al. “Ameloblastoma - a diagnostic problem”. British Dental Journal5 (2000): 243-244.
- Mohammed Asif S., et al. “Negligence or tumor aggressiveness: A case report of recurrent ameloblastoma”. SAGE Open Medical Case Reports 7 (2019): 2050313X19834416.
- Mendenhall WM., et al. “Ameloblastoma”. American Journal of Clinical Oncology6 (2007): 645-648.
- Regezi J., et al. “Oral pathology. Clinical pathological correlations”. Louis: Elsevier-Saunders 6 (2012): 270-277.
- Gardner DG., et al. “ In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours. Pathologies and genetics. Head and neck tumours. Lyon: IARC Press; 2005. p. 296-300.
- Soluk-tekkesin M and Wright JM. “The world health organization classification of odontogenic lesions: a summary of the changes of the 2017 (4th) edition”. Turkish Journal of Pathology
- Nadendla L. “Unusual imaging appearance of unicystic ameloblastoma”. Contemporary Clinical Dentistry4 (2012): 475-477.
- Meshram M., et al “Conservative Management of Unicystic Ameloblastoma in Young Patients: A Prospective Single-Center Trial and Review of Literature”. Journal of Maxillofacial and Oral Surgery3 (2017;): 333-341.
- Ahossi V., et al. “Mandibular plexiform unicystic ameloblastoma - about a case”. Odonto-Stomatological Review 38 (2009): 53-63.
- Bhutia O., et al. “Management of unicystic ameloblastoma of the mandible in a 5-year old child”. National Journal of Maxillofacial Surgery2 (2013): 232-234.
- Kalaskar R., et al. “Conservative management of unicystic ameloblastoma in a young child: Report of two cases”. Contemporary Clinical Dentistry4 (2011): 359-363.
- Manas Bajpai., et al. “Multilocular Unicystic Ameloblastoma of Mandible”. Hindawi Publishing Corporation, Case Reports in Dentistry (2013).
- Rosenstein T., et al. “Cystic ameloblastoma-behavior and treatment of 21 cases”. Journal of Oral and Maxillofacial Surgery11 (2001): 1311-1316.
- Neagu D., “Surgical management of ameloblastoma: Review of literature”. Journal of Clinical and Experimental Dentistry1 (2019): 70-75.
- Pogrel MA and Montes DM. “Is there a role for enucleation in the management of ameloblastoma?”. International Journal of Oral and Maxillofacial Surgery 38 (2009): 807-812.
- Hammarfjord O., et al. “Surgical treatment of recurring ameloblastoma, are there options?”. British Journal of Oral and Maxillofacial Surgery 51 (2013): 762-766.
- Gültekin SE., et al. “The landscape of genetic alterations in ameloblastomas relates to clinical features”. Virchows Archiv 472 (2018): 807-814.
- Gupta N., et al. “Unicystic ameloblastoma of the mandible”. Journal of Oral and Maxillofacial Pathology2 (2011): 228-231.
- Heikinheimo K., et al. “Novel Targets for the Treatment of Ameloblastoma”. Journal of Dental Research2 (2015): 237-240.
- Kurppa KJ., et al. “High frequency of BRAFV600E mutations in ameloblastoma: Recurrent oncogenic mutation in ameloblastoma”. The Journal of Pathology5 (2014): 492-498.
- Sweeney RT., et al. “Identification of recurrent SMO and BRAF mutations in ameloblastomas”. Nature Genetics7 (2014): 722-725.
- Brown NA., et al. “Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma”. Clinical Cancer Research21 (2014): 5517-5526.
- Sithanandam G., et al. “Complete coding sequence of a human B-RAF cDNA and detection of B-RAF protein kinase with isozyme specific antibodies”. Oncogene12 (1990): 1775-1780.
- Sithanandam G., et al. “B-RAF and a B-RAF pseudogene are located on 7q in man”. Oncogene4 (1992): 795-799.
- Davies H., et al. “Mutations of the BRAF gene in human cancer”. Nature 417 (2002): 949-954.
- Bollag G., et al. “Vemurafenib: the first drug approved for BRAF-mutant cancer”. Nature Reviews Drug Discovery11 (2012): 873-886.
- Fernandes GS., et al “Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation”. BMC Cancer1 (2018).
- Tan S., et al. “BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response”. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology1 (2016): e5-e7.
- Faden DL and Algazi A. “Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma”. Journal of the National Cancer Institute (2017): djw109.